Northern Light Venture Capital (NLVC) is a leading China-focused venture capital firm targeting early-stage opportunities of innovation and disruptive technology. Founded by Mr. Feng Deng in 2005, Northern Light has backed near 400 enterprises in TMT, advanced technology and healthcare industries. Leveraging significant investing and entrepreneurial expertise in both China and the United States, the NLVC team looks to support entrepreneurs with groundbreaking ideas and exceptional vision to develop lasting ventures that positively impact society. For more information: www.NLVC.com.
Established in 2002, CDH Investments is an alternative asset management firm with a focus on China. CDH is committed to building long-term, trusted partnerships with global investors and portfolio companies. From its roots in private equity, CDH Investments has expanded to become a diversified alternative asset management platform covering: Private Equity, Venture and Growth Capital, Real Estates, Mezzanine & Credit, Public Equities and Wealth Management. Having several offices in Hong Kong, Singapore, Beijing, Shanghai, and Shenzhen, CDH's integrated operations position the firm to capture investment opportunities at different stages across the corporate lifecycle and provide diversified risk and return alternatives to their investors.
Shenzhen Capital Group Company, Ltd. (“SCGC”) is a venture capital firm (“VC”) in China. SCGC was originallyco-founded by the Shenzhen Municipal Government and a group of private partners in August 1999, SCGC is now a privately and independently managed VC. Since its establishment, SCGC’s venture capital investments have focused on cultivating domesticand international companies, helping to shape national brands, and promoting economic transformation and emerging industries. SCGC has registered capital of 5.42 billion RMB and total asset under management (“AUM”) of 346.36 billion RMB.
SCGC primarily invests in innovative high-tech companies in emerging industries in their start-up, growth or pre-IPOstage. SCGC investments are extensive, including,but not limited to, investments in information technology (“IT”), internet, new media, healthcare, new energy, environment protection, chemical engineering, new material, advanced manufacturing, consumer goods, modern service, etc. As of March, 2020, SCGC is ranked the No.1 VC in Chinabased on the overall number of portfolio companies (1093), the total investment amount (50.0 billion RMB) and the number of portfolio companies that are listed on capital markets worldwide (160 companies listed in 16 different capital markets).
Zhejiang Haibang Investment Management Co., Ltd. was founded in 2011. The company's "Haibang Talent Fund" is the first domestic venture capital fund with the theme of "returnee talent entrepreneurship", focusing on life and health, digital economy, new materials and high-end manufacturing in key areas. The company has accumulated 14 funds and a number of special funds with a management capital of nearly 4 billion yuan, and has invested in more than 90 companies, of which 14 companies have finished IPOs, mergers and acquisitions, and more than 10 companies are actively preparing for the IPO process. Among them, each project has a certain degree of industry benchmarking and industry guiding significance in the province.
Lake Bleu Capital is a multi-billion-dollar asset management platform operating in Hong Kong and Shanghai. We specialize in healthcare investing in Asia/Greater China. Our clients include sovereign wealth funds, endowments & foundations, pension funds, and family offices globally.
With a long-term investment horizon, we manage strategies through both public and private equity with a primary focus on mid- to late-stage investments.
Lake Bleu Capital holds Hong Kong SFC-issued Type 9 (asset management) license and provides services only to professional investors.
HighLight Capital (HLC) is a health industry focused fund. We are dedicated to investing in leading life science enterprises which provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. HLC currently manages both RMB & USD fund with total AUM of over 16 billion USD. With extensive experience, we have accumulated unique insight into health-related industries and have established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO etc), medical technology (medical devices, IVD etc.) and consumer health (hospital chains, personal care etc.).
HLC portfolio includes high quality companies such as MINDRAY, WUXI, TIGERMED, PHAMARON, YUWELL, UNITED IMAGING, BRIGHTGENE, ZENTALIS, GENETRON HEALTH, KINTOUR MEDICAL, SANSURE BIOTECH, HONGENE, CHEMCLIN, SMOORE, BEABA etc.
Sinopharm Capital, focusing on healthcare equity investments, was co-founded by the management team and Sinopharm Group in 2012. The management team consists of professional healthcare experts inside and outside of Sinopharm Group. As one of the earliest healthcare investment institutions in China, Sinopharm Capital has deep understandings of healthcare industrial trend/operation and capital management. We closely cooperate with Sinopharm Group to capitalize on our industry resources in sourcing and assessing investment opportunities, adding value to our portfolio companies as well.
HM Capital is a healthcare focused investment firm within the Hillhouse Capital Group's ecosystem. HM Capital is committed to building an investment platform with a global view and local execution to help early and growth-stage healthcare companies achieve accelerated development by leveraging the ecosystems of affiliated operating companies, the top-tier Asian private equity firm, and the premier international healthcare institution.
Linden Asset Group (“LAG”) invests in revolutionary technologies, principally focusing on biotech and intelligent-tech. LAG aims to discover pioneers in the forefront of science from a long-term perspective, whose innovations would help ensure humanity lives in a healthier and happier way. With over 2 billion RMB in assets under management, LAG’s presence includes offices in China and Singapore.
Panlin Capital, founded in 2010, is a limited partnership established under the laws of the PRC and is dedicated to ventures in the field of healthcare and intelligent technology, which primarily investing in tech startups at series pre-A and A rounds. Focusing on the theme of “Technological Innovation leads Consumption Upgrade”, we proactively deploy investments in innovative drugs & high-end medical devices as well as intelligence application & equipment.
In healthcare field，our Portfolio companies include Kangtai, Hybribio, Shenogen, Ribo, Apollomics, GenFleet, Passiontec, FortBio, Cothera, ABM, Virogin, KingstronBio, Antekang Checg, Thorough Images, LangRui, OSMUNDA ,etc.
Hidragon Capital is an independent research-driven private equity fund manager, built by a group of experienced investors. Hidragon Capital focused on the investment of sector leaders and innovators within the Pharma, Medical services, BioTech, MedTech and various sub-sectors. Our portfolio includes：Ascentage Pharma, Genfleet Therapeutics, Allist Pharmaceutical, YHLO Biotech, Epimab Biotherapeutics, Genchem, Zhuoyi Biology, ZYAK Biotech, Xihua Scientific, Kangsheng Medical Devices.
CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs. The group’s total assets are 50 billion RMB, with 27000 employees. Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI, and also the first pharmaceutical stock in the 50-year history of HSI. On March 22, 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group.
At present, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin, and other provinces and cities. The products are sold in more than 100 countries and regions around the world, and 35 single varieties sold over 100 million RMB.
Shanghai Shanjin Asset Management Co., Ltd. (Shanjin Capital) was founded in 2016 . The current management scale exceeds 1 billion RMB.
As a private equity fund manager, the goal set by Shanjin Capital is to focus on core assets of China. Also, Shanjin Capital's investment is in the purpose of assisting investors to get a substantial share in the new round of China economic transformation.
Our investment fields focus on Key & Core Technology and Healthcare. In the aspect of Key & Core Technology, we deeply involved in 5G, AI and semiconductor also their subdivision tracks. We have invested in Cloudwalk, United Winner(688518.SH), Q&C silicon (605183.SH), SNC New Energy Technology, CorEnergy, Suzhou Huntersun, and Bailian.AI.
In the aspect of Healthcare, we focus on the fields of biotech, medical instruments, and molecular diagnostics. Our portfolio includes excellent enterprises such as Suzhou Zelgen Biopharmaceuticals (688266.SH), TINAVI (688277.SH), SHIP Biological, Genfleet Pharmaceutical, and Shanxi Micot, etc.
In the future, Shanjin team will adhere to the path of value investment, conduct in-depth research focus on Key & Core Technology companies with high technical barriers. We earnestly hope to grow with outstanding companies together and create long-term value for investors and society together.
TF Capital focuses on investment in the life sciences industry, primarily investing in early-stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.
South China Venture Capital (“SCVC”) is a professional asset management institution established in 2008 and with a focus on venture capital in the fields of biomedicine, semiconductor, artificial intelligence and other scientific and technological fields.
BOCOM Science and Technology Innovation Fund is China’s first bank-affiliated science and technology investment fund, with underlying investments aiming to be listed on the Science and Technology Innovation Board (STAR Market). The fund focuses on investing in artificial intelligence, new materials, bio-pharmaceuticals and next-generation information technology. The wholly-owned subsidiary of BOCOM International serves as fund manager, leveraging on the resources of the BOCOM Group to provide high-quality technology and innovation companies with full-scale comprehensive financial services.
Pu’en Guoxin Equity Investment Center (Limited Partnership) is jointly established by Guoxin Sichuang Investment Fund Management (Beijing) Co., Ltd., and a leading company in domestic pharmaceutical industry----CSPC (01093.HK), focusing on investing in innovative biotech company. Puen Guoxin aims to synergistically empower and enhance the value of invested projects through the combination of industrial capital and social capital, while creating income for investors and achieving a win-win situation for all parties.
Founded by senior experts in the field of medicine and healthcare, the core founding team is composed of scientist who have succeeded in starting a business in both US and China and senior manager of the world’s leading pharmaceutical companies. Team advantage complement, with valuable practical experience and resources in the pharmaceutical industry, and in-depth understanding of the latest medical research and development trends at home and abroad.
Lake Capital has long been focusing on investment opportunities in the field of healthcare, and has been deeply involved in the various sub-sectors and help potential businesses become leaders, help to introduce international leading products, technology to the Chinese market, providing more advanced and cost-effective medical products to the majority of medical professionals and patients in China.
The portfolio previously managed by the core team of Lake Capital cover innovative drugs, biosimilar drugs, and high-value-added medical devices and consumables, genetic immunotherapy and medical services.